Evidence map›Paper›PMID 25431338›Full record

ArticleJournal of cancer research and clinical oncology2015

The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.

Ke-Wang Luo, Chun-Hay Ko, Grace Gar-Lee Yue, Si Gao, Julia Kin-Ming Lee, Gang Li, Kwok-Pui Fung, Ping-Chung Leung, Andreas Evdokiou, Clara Bik-San Lau

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?Breast cancer : basic and clinical research · 2019
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ke-Wang LuoInstitute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Chun-Hay Ko
Grace Gar-Lee Yue
Si Gao
Julia Kin-Ming Lee
Gang Li
Kwok-Pui Fung
Ping-Chung Leung
Andreas Evdokiou
Clara Bik-San Lau
Chinese University of Hong Kong · CNUniversity of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn previous studies, we demonstrated that green tea (Camellia sinensis, CS) water extract had potent anti-tumor and anti-metastasis effects in the 4T1 mouse breast cancer xenograft model, and the metronomic regimen (0.0125 mg/kg twice a week for 4 weeks) of zoledronic acid (ZOL) was also effective in decreasing tumor burden and metastasis when compared with the conventional regimen. This study aimed to investigate the combined use of CS water extract and metronomic ZOL against tumor metastasis and bone destruction in MDA-MB-231-TXSA human breast cancer.

methodsFemale nude mice were injected with MDA-MB-231-TXSA cells into the marrow space of tibia and were treated with CS water extract and/or metronomic ZOL for 4 weeks. Tumor growth and metastasis to lungs and livers were assessed by in vivo bioluminescence imaging. Abilities of migration and invasion of MDA-MB-231-TXSA cells were also evaluated in vitro.

resultsOur results demonstrated that combination of CS and ZOL had the most potent effects on tumor burden and metastasis to bone, lung and liver, while treatment with CS or ZOL alone significantly protected the bone from cancer-induced osteolysis. In vitro, the combined use of CS + ZOL significantly inhibited MDA-MB-231-TXSA cell migration and invasion. Mechanistic zymography studies showed that the enzyme activities of MMP-9 and MMP-2 were significantly suppressed by CS and CS + ZOL.

conclusionsThe combination of CS plus metronomic ZOL demonstrated potent anti-tumor, anti-metastasis and anti-osteolysis effects against breast cancer, suggesting the potential clinical application against breast cancer patients.

Indexed as

Camellia sinensisMammary Neoplasms, ExperimentalAdministration, MetronomicAnimalsBone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsCell Line, TumorDiphosphonatesDrug Therapy, CombinationFemaleImidazolesLiver NeoplasmsLuminescent MeasurementsLung NeoplasmsMatrix Metalloproteinase 2Bone Density Conservation AgentsDiphosphonatesImidazolesMatrix Metalloproteinase 2Matrix Metalloproteinase 9Plant ExtractsZoledronic Acid

Identifiers

PMID25431338
PMCPMC11824012
OpenAlexW2051652224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.